Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| LLY | PRESS-RELEASE | bullish | 5/10 | Eli Lilly completed its acquisition of AtaiBeckley, a clinical-stage biopharma developing neuroplastogens for mental hea | Sep 11, 2026 |
| TPST | PRESS-RELEASE | bearish | 6/10 | Tempest Therapeutics announced a private placement of ~3.1M shares and warrants at $0.805/unit, raising ~$2.5M in gross | Sep 11, 2026 |
| ALLR | PRESS-RELEASE | neutral | 4/10 | Allarity Therapeutics announced that its newly formed SPAC subsidiary, Allarity Acquisition Corp., filed an S-1 registra | Sep 11, 2026 |
| ELAN | PRESS-RELEASE | neutral | 1/10 | Elanco Animal Health announced it will host a conference call on November 6, 2026 to discuss its Q3 2026 results. | Sep 11, 2026 |
| CATX | PRESS-RELEASE | neutral | 3/10 | Perspective Therapeutics announced that updated data on its [212Pb]VMT-α-NET program for neuroendocrine tumors (NETs) ha | Sep 11, 2026 |
| SEPN | PRESS-RELEASE | neutral | 2/10 | Septerna granted a 275,000-share non-qualified stock option inducement award to newly appointed CMO Rajiv Patni under th | Sep 10, 2026 |
| VRCA | PRESS-RELEASE | bullish | 5/10 | Verrica Pharmaceuticals announced positive post-hoc data from Phase 3 trials of YCANTH for molluscum contagiosum, showin | Sep 10, 2026 |
| CAMP | PRESS-RELEASE | neutral | 4/10 | CAMP4 received MHRA authorization to include UK sites in its global Phase 1/2 trial of CMP-002 for SYNGAP1-related disor | Sep 10, 2026 |
| MDCX | PRESS-RELEASE | bullish | 6/10 | Medicus Pharma published the abridged Clinical Study Report for its Phase 2 SkinJect® trial on ClinicalTrials.gov, confi | Sep 10, 2026 |
| CRVO | PRESS-RELEASE | bullish | 5/10 | CervoMed announced that neflamapimod will be featured in a late-breaking oral presentation at the ISFTD Annual Meeting i | Sep 10, 2026 |
| PRLD | PRESS-RELEASE | neutral | 4/10 | Prelude Therapeutics announced FDA clearance to begin a Phase 1 study of PRT13722, an oral KAT6A selective degrader for | Sep 10, 2026 |
| TEVA | PRESS-RELEASE | neutral | 5/10 | Teva priced a ~$4.9B multi-tranche senior notes offering across five maturities (2032-2037), with proceeds to fund the c | Sep 10, 2026 |
| IRON | PRESS-RELEASE | bullish | 7/10 | Disc Medicine presented positive initial Phase 2 data for DISC-3405 in polycythemia vera (PV) at SOHO 2026, showing sign | Sep 9, 2026 |
| RPRX | PRESS-RELEASE | bearish | 5/10 | Royalty Pharma announced that Novartis' Phase 3 HORIZON trial for pelacarsen failed to meet its primary endpoint in athe | Sep 4, 2026 |
| RNTX | PRESS-RELEASE | neutral | 3/10 | Rein Therapeutics announced a late-breaking poster presentation on LTI-03 at the ERS 2026 Congress, with data already pu | Sep 4, 2026 |
| VRXA | PRESS-RELEASE | neutral | 2/10 | Veraxa Biotech announced the appointment of Raju Willener as CFO, effective immediately. Willener brings over 30 years o | Sep 4, 2026 |
| IMRN | PRESS-RELEASE | neutral | 4/10 | Immuron announced an exclusive U.S. distribution agreement with Calmino group AB for PROIBS®, a medical device for diges | Sep 4, 2026 |
| BIIB | PRESS-RELEASE | neutral | 4/10 | Biogen (BIIB) and partner Stoke Therapeutics (STOK) presented positive 4-year open-label extension data for zorevunersen | Sep 3, 2026 |
| LTGO | PRESS-RELEASE | bullish | 7/10 | Latigo Biotherapeutics reported Q2 2026 results with a net loss of $25.8M (EPS -$27.59 vs consensus -$0.46, a mechanical | Sep 3, 2026 |
| KMDA | PRESS-RELEASE | neutral | 2/10 | Kamada announced a tax ruling from the Israel Tax Authority regarding its previously declared $0.17 per share cash divid | Sep 3, 2026 |
| PRFX | PRESS-RELEASE | neutral | 4/10 | PRF Technologies reported a net loss of $2.8M for H1 2026 (up from $2.3M) but strengthened its cash position to $11.6M a | Sep 3, 2026 |
| EIKN | PRESS-RELEASE | neutral | 3/10 | Eikon Therapeutics appointed Dr. Ching-Pin Chang as EVP and Chief Scientific Officer. Dr. Chang joins from Bristol Myers | Sep 3, 2026 |
| LQDA | PRESS-RELEASE | bullish | 6/10 | No summary provided | Sep 3, 2026 |
| BIIB | PRESS-RELEASE | bullish | 7/10 | Biogen and Eisai announced that China's NMPA approved the subcutaneous autoinjector formulation of LEQEMBI (lecanemab) f | Sep 3, 2026 |
| SCTX | PRESS-RELEASE | bullish | 7/10 | Scribe Therapeutics reported Q2 2026 collaboration revenue of $1.9M (down 61% YoY from $4.9M) and a net loss of $6.5M ($ | Sep 2, 2026 |
| ATTO | PRESS-RELEASE | bullish | 7/10 | Attovia Therapeutics reported Q2 2026 results with a net loss of $20.7M (vs $14.4M in Q2 2025) and minimal collaboration | Sep 2, 2026 |
| CANF | PRESS-RELEASE | bearish | 6/10 | Can-Fite BioPharma announced a warrant exercise agreement to raise ~$4.0M gross proceeds by immediately exercising 1,591 | Sep 2, 2026 |
| IRD | PRESS-RELEASE | neutral | 5/10 | Opus Genetics announced plans to present topline Phase 1/2 Cohort 1 data for OPGx-BEST1 gene therapy on September 9, 202 | Sep 2, 2026 |
| QNTM | PRESS-RELEASE | neutral | 3/10 | Quantum BioPharma (QNTM) announced it has applied for a voluntary delisting from the Canadian Securities Exchange (CSE), | Sep 1, 2026 |
| TLX | PRESS-RELEASE | bullish | 6/10 | Telix completed enrollment (350 patients) in the Phase 3 BiPASS study evaluating Illuccix/Gozellix for pre-biopsy prosta | Sep 1, 2026 |